Company: PHAT
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034183
Chunk: 127

Company: Phathom Pharmaceuticals, Inc.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 16
Chunk 127
---
 Loan and Security Agreement, dated May 9, 2023, by and among Hercules Capital and the Registrant
     
    10-Q
     
    5-10-2023
     
    10.1

    10.25^
     
    First Amendment to Vonoprazan Commercial Supply Agreement, dated August 1, 2022, by and among Evonik Operations GmbH and the Registrant
     
    10-Q
     
    8-10-2023
     
    10.1

    10.26†
     
    First Amendment to the Commercial Supply Agreement, dated as of December 6, 2023, by and among Catalent Pharma Solutions, LLC and the Registrant
     
    10-K
     
    3-7-2024
     
    10.26

    10.27^
     
    Fourth Amendment to the Loan and Security Agreement, dated December 14, 2023, by and among Hercules Capital and the Registrant
     
    10-K
     
    3-7-2024
     
    10.27

    10.28#
     
    Phathom Pharmaceuticals Inc. 2024 Bonus Plan
     
    10-K
     
    3-7-2024
     
    10.28

    10.29†
     
    Letter Agreement to Vonoprazan Commercial Supply Agreement, dated September 4, 2024, by and among Evonik Operations GmbH and the Registrant
     
    10-Q
     
    11-7-2024
     
    10.1

    10.30
     
    Joinder Agreement dated December 23, 2024 by and among  CO Finance III LVS LX LP and the Registrant

    X

148

    19
     
    Phathom Pharmaceuticals, Inc. Insider Trading Compliance Policy and Procedures

    X

    23.1
     
    Consent of Independent Registered Public Accounting Firm

    X

    24.1
     
    Power of Attorney 

    X

    31.1
     
    Certification of Chief Executive Officer of Phathom Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange